T. Susanna Meijer , 1 , Mark C. Burgmans 1 , Marta Fiocco 2 , Lioe-Fee de Geus-Oei 1 , 3 , Ellen Kapiteijn 4 , Eleonora M. de Leede 5 , Christian H. Martini 6 , Rutger W. van der Meer 1 , Fred G. J. Tijl 7 , Alexander L. Vahrmeijer 5
14 February 2019
To investigate the safety and toxicity of percutaneous hepatic perfusion with melphalan (M-PHP) with the Delcath Systems’ second-generation (GEN 2) filter and compare the outcomes with historical data from studies using the first-generation filter.
A prospective, single-arm, single-center phase II study was carried out including 35 patients with unresectable, histologically confirmed liver metastases from ocular melanoma between February 2014 and June 2017. Main exclusion criteria were extrahepatic disease and age > 75 years. M-PHP was performed with melphalan 3 mg/kg (maximum dose 220 mg). Safety and toxicity were assessed according to the Common Terminology Criteria for Adverse Events version 4.03.
A total of 67 M-PHPs were performed in 35 patients (median 2 procedures). Although hematologic grade 3/4 events were seen in the majority of patients (thrombocytopenia 54.5%, leukopenia 75.6%, neutropenia 66.7%, anemia (only grade 3) 18.1%), these were all well manageable or self-limiting. Of the non-hematologic grade 3 events ( n = 14), febrile neutropenia ( n = 3), pulmonary emboli ( n = 2) and post-procedural hemorrhage ( n = 2) were most common. A case of sepsis with bacterial pharyngitis was the only non-hematologic grade 4 event. Prior therapy for liver metastases was found to be a predictor of late grade 3/4 neutropenia with an odds ratio of 5.5 (95% CI 1.4–21.7).